340 related articles for article (PubMed ID: 29298800)
1. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
[TBL] [Abstract][Full Text] [Related]
2. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
Diabetes Obes Metab; 2019 Jul; 21(7):1737-1744. PubMed ID: 30830727
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.
Ida S; Kaneko R; Murata K
Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163
[TBL] [Abstract][Full Text] [Related]
9. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Komiya I; Yamamoto A; Sunakawa S; Wakugami T
Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
[TBL] [Abstract][Full Text] [Related]
11. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
[TBL] [Abstract][Full Text] [Related]
12. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
[TBL] [Abstract][Full Text] [Related]
13. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
[TBL] [Abstract][Full Text] [Related]
15. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
16. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
17. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.
Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S;
J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640
[TBL] [Abstract][Full Text] [Related]
18. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
[TBL] [Abstract][Full Text] [Related]
19. Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.
Yamashita S; Okazaki M; Okada T; Masuda D; Yokote K; Arai H; Araki E; Ishibashi S
J Atheroscler Thromb; 2021 Sep; 28(9):974-996. PubMed ID: 33536398
[TBL] [Abstract][Full Text] [Related]
20. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]